Integration of a severe immune-related adverse events predictive model with efficacy biomarkers enables precise stratification in NSCLC immunotherapy: insights from the phase 3 ORIENT-11 study

Cancer Immunology, Immunotherapy · Published 2026-08-26 · Journal article · DOI 10.1007/s00262-026-04511-y

Free full text

Authors (16)

Yue Peng, Ling Wen, Jiayi Shen, Jianhua Zhan, Huaqiang Zhou, Jiaqing Liu, Gang Chen, Yaxiong Zhang, Shen Zhao, Yuanyuan Zhao, Yan Huang, Wenfeng Fang, Yunpeng Yang, Haishuang Sun, Li Zhang, Dongchen Sun

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Peng, Y., Wen, L., Shen, J., et al. (2026). Integration of a severe immune-related adverse events predictive model with efficacy biomarkers enables precise stratification in NSCLC immunotherapy: insights from the phase 3 ORIENT-11 study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04511-y

Related articles